肿瘤细胞治疗研究
英文原题：Efficiency of Immunological Blood Biomarkers in Predicting Chemotherapy Response and Survival Outcome for Non-Targetable Advanced Non-Small Cell Lung Cancer Patients.
我们的研究结果表明，sCD25和NLR分别有潜力作为PFS和OS的指标。此外，化疗前%NKT和化疗后%NK细胞可能为监测化疗反应提供见解。这项初步研究确定了潜在的候选生物标志物，有待进一步研究以确认其临床实用性。
化疗是不可靶向的晚期非小细胞肺癌（NSCLC）的主要治疗方法。然而，目前可用于预测临床结局和监测治疗反应的生物标志物很少。
收集42例接受化疗的不可靶向晚期NSCLC患者化疗前和化疗后的血液样本。采用流式细胞术检测循环免疫细胞及Treg亚群，并通过多重微珠法分析人免疫检查点生物标志物水平。
在筛选出用于生存分析的有效生物标志物后，高化疗前sCD25（≥499.52 pg/mL；4.52 vs 14.98个月，p = 0.030）和化疗后sCD25（≥515.23 pg/mL；3.90 vs 21.25个月，p = 0.004）与较差的中位无进展生存期（PFS）相关。化疗前中性粒细胞与淋巴细胞比值（NLR）升高（比值≥6.9；5.15 vs 21.54个月，p = 0.008）和化疗后NLR升高（比值≥3.1；10个月OS 50.35% vs 83.57%，p = 0.014）与较短的总生存期（OS）相关。此外，化疗前%NKT细胞升高（≥6.8%）与临床获益率（CBR）改善相关（2.72 vs 3.97个月，p = 0.013），而化疗后%NK细胞较高（≥23.1%）与4个月时快速总体缓解率（ORR）相关（82.05% vs 25%，p = 0.035）。
PURPOSE: Chemotherapy is the main therapy for non-targetable advanced non-small cell lung cancer (NSCLC). Nevertheless, few biomarkers are currently available for predicting clinical outcomes and monitoring treatment response. PATIENTS AND METHODS: The blood samples of 42 patients with non-targetable advanced NSCLC who received chemotherapy were collected before chemotherapy and after chemotherapy. The circulating immune cells and subpopulation Treg were investigated using flow cytometry, and human immune checkpoint biomarker levels were analysed by multiplex bead-based assay. RESULTS: After selecting the effective biomarkers for survival analysis, high pre-chemotherapy sCD25 (≥499.52 pg/mL; 4.52 vs 14.98 months, p = 0.030) and post-chemotherapy (≥515.23 pg/mL; 3.90 vs 21.25 months, p = 0.004) were associated with poorer median progression-free survival (PFS). An increase in pre-chemotherapy neutrophil to lymphocyte ratio (NLR) (ratio ≥ 6.9; 5.15 vs 21.54 months, p = 0.008) and post-chemotherapy NLR (ratio ≥ 3.1; 10-month OS 50.35% vs 83.57%, p = 0.014) was correlated with shorter overall survival (OS). Moreover, increased pre-chemotherapy %NKT cells (≥6.8%) were linked to improved clinical benefit rate (CBR) (2.72 vs 3.97 months, p = 0.013), while higher post-chemotherapy %NK cells (≥23.1%) were associated with rapid overall response rate (ORR) at 4 months (82.05% vs 25%, p = 0.035). CONCLUSION: Our findings suggest that sCD25 and NLR show potential as indicators of PFS and OS, respectively. Additionally, pre-chemotherapy %NKT and post-chemotherapy %NK cells may provide insight into monitoring chemotherapy response. This pilot study identified potential candidate biomarkers for further investigation to confirm their clinical utility.
MEMBER ACCOUNT
登录成功会直接打开下一页。
